On Tuesday, BridgeBio Pharma Inc (NASDAQ: BBIO) was -3.46% drop from the session before settling in for the closing price of $74.24. A 52-week range for BBIO has been $25.34 – $75.10.
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.04%. When this article was written, the company’s average yearly earnings per share was at -20.76%. With a float of $164.53 million, this company’s outstanding shares have now reached $192.63 million.
BridgeBio Pharma Inc (BBIO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward BridgeBio Pharma Inc stocks. The insider ownership of BridgeBio Pharma Inc is 14.62%, while institutional ownership is 87.80%. The most recent insider transaction that took place on Dec 04 ’25, was worth 2,975,913. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $74.40, taking the stock ownership to the 775,686 shares. Before that another transaction happened on Dec 05 ’25, when Company’s Chief Executive Officer sold 40,000 for $73.31, making the entire transaction worth $2,932,563. This insider now owns 755,686 shares in total.
BridgeBio Pharma Inc (BBIO) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.37 earnings per share (EPS) during the time that was less than consensus figure (set at -1.09) by -0.28. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.76% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
You can see what BridgeBio Pharma Inc (BBIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.53 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Looking closely at BridgeBio Pharma Inc (NASDAQ: BBIO), its last 5-days average volume was 1.74 million, which is a drop from its year-to-date volume of 2.79 million. As of the previous 9 days, the stock’s Stochastic %D was 65.43%.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 89.61%, which indicates a significant increase from 67.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.48 in the past 14 days, which was higher than the 2.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $62.46, while its 200-day Moving Average is $46.48. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $73.77. Second resistance stands at $75.87. The third major resistance level sits at $77.03. If the price goes on to break the first support level at $70.52, it is likely to go to the next support level at $69.36. Now, if the price goes above the second support level, the third support stands at $67.26.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are 192,709K outstanding shares of the company, which has a market capitalization of 13.81 billion. As of now, sales total 221,900 K while income totals -535,760 K. Its latest quarter income was 120,700 K while its last quarter net income were -182,740 K.
